 Organovo Holdings, Inc. is an early-stage biotechnology company developing and utilizing highly customized 3D human tissues as dynamic models of health and diseased human biology for internal drug development. Organovo is transitioning its short-term offering from a heavily service-based business in 2019 to drug candidate development, projecting multiple INDs by 2025. 